Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 3 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

0
Player Avatar anne1730 (49.31) Submitted: 7/1/2010 5:54:25 PM : Outperform Start Price: $4.72 ELN Score: +174.85

good product;; good research

Featured Broker Partners


Advertisement